3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Breast
1
Conditions
Neoplasms
8
Lymphoma, Non-Hodgkin
5
Sarcoma
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Lymphoma, Mantle-Cell
4
Lymphoma, Large-Cell, Immunoblastic
4
Lymphoma, Large B-Cell, Diffuse
4
Lymphoma, Follicular
4
Lymphoma, B-Cell, Marginal Zone
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Burkitt Lymphoma
4
Neoplasm Metastasis
3
Colorectal Neoplasms
3
Vulvar Neoplasms
2
Vaginal Neoplasms
2
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Urethral Neoplasms
2
Testicular Neoplasms
2
Prostatic Neoplasms
2
Penile Neoplasms
2
Ovarian Neoplasms
2
Lymphoma
2
Fallopian Tube Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Carcinoma, Hepatocellular
2
Unspecified Childhood Solid Tumor, Protocol Specific
1
Stomach Neoplasms
1
Solid Tumors
1
Interventions
Gemcitabine
13
Cisplatin
9
Capecitabine
7
durvalumab
6
pembrolizumab
4
tremelimumab
3
S 1 (combination)
3
Nivolumab
3
AZD 6244
3
Ramucirumab
2
Fluorouracil
2
130-nm albumin-bound paclitaxel
2
vandetanib
1
trifluridine tipiracil drug combination
1
trametinib
1
tocilizumab
1
titanium silicide
1
sacituzumab govitecan
1
poly ICLC
1
futibatinib
1
fludarabine
1
cemiplimab
1
binimetinib
1
aflibercept
1
Tegafur
1
TAS-116
1
Psilocybin
1
Peptides
1
Oxaliplatin
1
NUC-1031
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Biliary Tract Neoplasms
×
aflibercept
×
Clear all
NCT01843725
2018-01-31
MOMENTUM1
Jules Bordet Institute
Phase 1
Completed
37 enrolled